Biogen Amevive Requires More Study For Multiple Cycles Of Therapy
Executive Summary
Additional examination of multi-course therapy with Biogen's antipsoriatic Amevive should be conducted to create a more robust picture of long-term risk, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee suggested May 23